BR112023020123A2 - Agentes heterobivalentes e homobivalentes que alvejam proteína alfa de ativação de fibroblasto alfa e/ou antígeno de membrana específico da próstata - Google Patents
Agentes heterobivalentes e homobivalentes que alvejam proteína alfa de ativação de fibroblasto alfa e/ou antígeno de membrana específico da próstataInfo
- Publication number
- BR112023020123A2 BR112023020123A2 BR112023020123A BR112023020123A BR112023020123A2 BR 112023020123 A2 BR112023020123 A2 BR 112023020123A2 BR 112023020123 A BR112023020123 A BR 112023020123A BR 112023020123 A BR112023020123 A BR 112023020123A BR 112023020123 A2 BR112023020123 A2 BR 112023020123A2
- Authority
- BR
- Brazil
- Prior art keywords
- prostate
- agents
- specific membrane
- membrane antigen
- homobivalent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasonic imaging preparations
- A61K49/221—Echographic preparations; Ultrasonic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acoustics & Sound (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170035P | 2021-04-02 | 2021-04-02 | |
| PCT/US2022/023374 WO2022212958A1 (en) | 2021-04-02 | 2022-04-04 | Heterobivalent and homobivalent agents targeting fibroblast activation protein alpha and/or prostate-specific membrane antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023020123A2 true BR112023020123A2 (pt) | 2024-01-23 |
Family
ID=83459940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023020123A BR112023020123A2 (pt) | 2021-04-02 | 2022-04-04 | Agentes heterobivalentes e homobivalentes que alvejam proteína alfa de ativação de fibroblasto alfa e/ou antígeno de membrana específico da próstata |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240382629A1 (https=) |
| EP (1) | EP4313049A4 (https=) |
| JP (1) | JP2024514528A (https=) |
| KR (1) | KR20230165818A (https=) |
| CN (1) | CN117255685A (https=) |
| AU (1) | AU2022252419A1 (https=) |
| BR (1) | BR112023020123A2 (https=) |
| CA (1) | CA3214070A1 (https=) |
| IL (1) | IL307405A (https=) |
| MX (2) | MX2023011599A (https=) |
| WO (1) | WO2022212958A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| AU2023347470A1 (en) | 2022-09-23 | 2025-04-10 | Nuclidium Ag | High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof |
| CN117883585A (zh) * | 2022-10-14 | 2024-04-16 | 无锡诺宇医药科技有限公司 | 靶向成纤维细胞活化蛋白的药物及其应用 |
| WO2024222888A1 (zh) * | 2023-04-27 | 2024-10-31 | 中国科学院上海药物研究所 | 一种fap抑制剂和靶向fap核素探针及其应用 |
| US12440585B2 (en) * | 2023-09-12 | 2025-10-14 | Curadel Surgical Innovations, Inc. | Zwitterionic metal chelators |
| WO2025087229A1 (zh) * | 2023-10-27 | 2025-05-01 | 四川科伦博泰生物医药股份有限公司 | 一类喹啉结构的配体化合物及其放射性或非放射性标记物以及应用 |
| KR20250062978A (ko) * | 2023-10-31 | 2025-05-08 | 서울대학교병원 | 신규한 전립선 특이적 막 항원 리간드 및 이의 용도 |
| WO2025119908A1 (en) * | 2023-12-06 | 2025-06-12 | Bracco Imaging Spa | Psma-targeting fluorescent probes |
| WO2025163029A1 (en) | 2024-01-31 | 2025-08-07 | Bracco Imaging Spa | Psma-targeting bimodal and heterobivalent fluorescent agents |
| CN117700485B (zh) * | 2024-02-04 | 2024-04-16 | 山东大学 | 一种同时靶向psma和fap的化合物及其制备方法与应用 |
| WO2025167951A1 (zh) * | 2024-02-07 | 2025-08-14 | 苏州博锐创合医药有限公司 | 一种成纤维细胞活化蛋白抑制剂 |
| CN118271393B (zh) * | 2024-05-31 | 2024-09-03 | 中国药科大学 | 一种靶向fap的二聚化合物及其探针和应用 |
| CN119080743B (zh) * | 2024-08-30 | 2026-01-06 | 北京师范大学 | 靶向psma和fap的双重靶向化合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013107820A1 (en) * | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| EA202090776A1 (ru) * | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| SG11202007180QA (en) * | 2018-02-06 | 2020-08-28 | Univ Heidelberg | Fap inhibitor |
| CA3093694A1 (en) * | 2018-03-12 | 2019-09-19 | Memorial Sloan Kettering Cancer Center | Bispecific binding agents and uses thereof |
| US11279698B2 (en) * | 2018-11-20 | 2022-03-22 | Cornell University | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
| CN113292538A (zh) * | 2021-05-10 | 2021-08-24 | 北京肿瘤医院(北京大学肿瘤医院) | 靶向肿瘤相关成纤维细胞激活蛋白的化合物及其制备方法和应用与靶向fap的肿瘤显影剂 |
-
2022
- 2022-04-04 BR BR112023020123A patent/BR112023020123A2/pt unknown
- 2022-04-04 MX MX2023011599A patent/MX2023011599A/es unknown
- 2022-04-04 US US18/553,092 patent/US20240382629A1/en active Pending
- 2022-04-04 JP JP2023560919A patent/JP2024514528A/ja active Pending
- 2022-04-04 CN CN202280032772.6A patent/CN117255685A/zh active Pending
- 2022-04-04 EP EP22782372.1A patent/EP4313049A4/en active Pending
- 2022-04-04 IL IL307405A patent/IL307405A/en unknown
- 2022-04-04 WO PCT/US2022/023374 patent/WO2022212958A1/en not_active Ceased
- 2022-04-04 KR KR1020237037723A patent/KR20230165818A/ko active Pending
- 2022-04-04 AU AU2022252419A patent/AU2022252419A1/en active Pending
- 2022-04-04 CA CA3214070A patent/CA3214070A1/en active Pending
-
2023
- 2023-09-29 MX MX2026000948A patent/MX2026000948A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117255685A (zh) | 2023-12-19 |
| US20240382629A1 (en) | 2024-11-21 |
| JP2024514528A (ja) | 2024-04-02 |
| WO2022212958A1 (en) | 2022-10-06 |
| MX2023011599A (es) | 2024-02-02 |
| MX2026000948A (es) | 2026-03-02 |
| EP4313049A1 (en) | 2024-02-07 |
| IL307405A (en) | 2023-12-01 |
| EP4313049A4 (en) | 2026-01-21 |
| CA3214070A1 (en) | 2022-10-06 |
| KR20230165818A (ko) | 2023-12-05 |
| AU2022252419A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023020123A2 (pt) | Agentes heterobivalentes e homobivalentes que alvejam proteína alfa de ativação de fibroblasto alfa e/ou antígeno de membrana específico da próstata | |
| MX2020004807A (es) | Agentes radioterapeuticos y de imagenologia que se dirigen a proteina-alfa de activacion fibroblastos (fap-alfa). | |
| PH12023550266A1 (en) | Anti-ceacam5 antibodies and conjugates and uses thereof | |
| BR112021015036A2 (pt) | Tratamento para câncer com imunoconjugados do anticorpo ror1 | |
| CY1123030T1 (el) | Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων | |
| AR115418A1 (es) | ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| BR112018072101A2 (pt) | sistemas e métodos para tratamento cosmético da pele com ultrassom | |
| BR112018014671A2 (pt) | moléculas que ativam seletivamente células t reguladoras para o tratamento das doenças autoimunes | |
| MX2024005705A (es) | Composiciones de liquidos ionicos. | |
| CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| CL2023001377A1 (es) | Anticuerpos anti-npr1 y usos de los mismos | |
| BR112021025645A2 (pt) | Degradação de proteína alvo de parp14 para uso em terapia | |
| MX2023005179A (es) | Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas. | |
| CY1114614T1 (el) | Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα | |
| MX2019007350A (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
| BR112021017810A2 (pt) | Anticorpos tsg-6 e usos dos mesmos | |
| MX2020012351A (es) | Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando. | |
| CO2024007212A2 (es) | Péptidos inmunogénicos magea1, proteínas de unión que reconocen péptidos inmunogénicos magea1, y usos de estos | |
| MX2024002781A (es) | Anticuerpos capaces de unirse a cumulo de diferenciacion 27 (cd27), variantes de los mismos y usos de los mismos. | |
| BR112023023558A2 (pt) | Anticorpos anti-tmprss6 e usos dos mesmos | |
| MX2025007229A (es) | Tratamiento de la enfermedad autoinmunitaria | |
| ES2111002T3 (es) | Factor activador de macrofagos derivado de la proteina de fijacion de vitamina d. | |
| WO2019246176A8 (en) | Anti-factor xii/xiia antibodies and uses thereof | |
| BR112021017863A2 (pt) | Proteína de ligação de antígeno de membrana específico de próstata, composição, método para produzir a proteína de ligação de antígeno de membrana específico de próstata |